Florence, Italy – Shanghai, China 16/04/2026 – Molteni Farmaceutici and Evive Biotech today announced a strategic agreement granting Molteni Farmaceutici exclusive rights to commercialize Ryzneuta® (efbemalenograstim alfa) in Italy and Poland.

Ryzneuta® represents a next-generation, long-acting granulocyte colony-stimulating factor (G-CSF), designed to address chemotherapy-induced neutropenia—one of the most significant and limiting complications in oncology treatment. With its advanced profile, Ryzneuta® aims to set a new standard in supportive care, improving both patient management and treatment continuity.

Under the terms of the agreement, Molteni Farmaceutici will lead regulatory, market access, and commercialization activities across the licensed territories, capitalizing on its established leadership and track record in oncology supportive care.

This partnership reflects a shared ambition to accelerate access to innovative therapies and to elevate the standard of care for patients undergoing chemotherapy, combining Evive Biotech’s scientific innovation with Molteni Farmaceutici’s strong execution capabilities and deep understanding of local markets.

“This agreement marks a meaningful step forward in strengthening our position in oncology supportive care and in upgrading our Portfolio” said Gianluca Corbinelli, CEO at Molteni Farmaceutici.
“Ryzneuta® stands out as an innovative and forward-looking solution in the management of neutropenia. We are committed to bringing this therapy rapidly to patients in Italy and Poland, further reinforcing our role as a trusted partner in hospital and specialty care.”

“We are proud to partner with Molteni Farmaceutici, whose expertise and focus in oncology supportive care make them uniquely positioned to unlock the full potential of Ryzneuta® in these key European markets,” said Dr. Yuhong Geng, Executive President at Yifan Pharmaceutical Co., Ltd.
“Together, we aim to deliver a new generation therapy that can meaningfully improve patient outcomes and support oncologists in their daily clinical practice.”

Ryzneuta® has demonstrated a robust efficacy and safety profile in clinical development as a long-acting G-CSF, offering a differentiated approach to the prevention of chemotherapy-induced neutropenia and its associated complications.

The agreement underscores both companies’ commitment to innovation, speed of execution, and delivering tangible value to patients and healthcare systems.

About Molteni Farmaceutici

Molteni Farmaceutici is an Italian pharmaceutical company with a long-standing heritage and a strong focus on specialty care. The company is recognized for its commitment to excellence in oncology supportive care and hospital-based treatments, delivering high-quality therapies that improve patient outcomes and quality of life.

About Evive Biotech

Evive Biotech, a subsidiary of Yifan Pharmaceutical, is a global biopharmaceutical company. Founded in 2004, they currently have operations in the US, EU, Singapore, and China. As one of the top biopharmaceutical companies to develop innovative therapies from China for the world, Evive adopts a holistic approach to drug development, combining exceptional preclinical and clinical research capabilities with world-class in-house manufacture and regulatory expertise as well as extensive global drug development experience.